Excessive Dopamine Research Articles

Developmental pyrethroid exposure causes a neurodevelopmental disorder phenotype in mice.

Neurodevelopmental disorders (NDDs) are a widespread and growing public health challenge, affecting as many as 17% of children in the United States. Recent epidemiological studies have implicated ambient exposure to pyrethroid pesticides during pregnancy in the risk for NDDs in the unborn child. Using a litter-based, independent discovery-replication cohort design, we exposed mouse dams orally during pregnancy and lactation to the Environmental Protection Agency's reference pyrethroid, deltamethrin, at 3 mg/kg, a concentration well below the benchmark dose used for regulatory guidance. The resulting offspring were tested using behavioral and molecular methods targeting behavioral phenotypes relevant to autism and NDD, as well as changes to the striatal dopamine system. Low-dose developmental exposure to the pyrethroid deltamethrin (DPE) decreased pup vocalizations, increased repetitive behaviors, and impaired both fear conditioning and operant conditioning. Compared with control mice, DPE mice had greater total striatal dopamine, dopamine metabolites, and stimulated dopamine release, but no difference in vesicular dopamine capacity or protein markers of dopamine vesicles. Dopamine transporter protein levels were increased in DPE mice, but not temporal dopamine reuptake. Striatal medium spiny neurons showed changes in electrophysiological properties consistent with a compensatory decrease in neuronal excitability. Combined with previous findings, these results implicate DPE as a direct cause of an NDD-relevant behavioral phenotype and striatal dopamine dysfunction in mice and implicate the cytosolic compartment as the location of excess striatal dopamine.

Repetitive transcranial magnetic stimulation rescues simulated space complex environment-induced emotional and social impairments by enhancing neuronal excitability in the medial prefrontal cortex.

Studies have shown that spaceflight affects the emotional and social performance of astronauts. Identifying the neural mechanisms underlying the emotional and social effects of spacefaring-specific environments is essential to specify targeted treatment and prevention interventions. Repetitive transcranial magnetic stimulation (rTMS) has been shown to improve the neuronal excitability and is used to treat psychiatric disorders such as depression. To study the changes of excitatory neuron activity in medial prefrontal cortex (mPFC) in simulated space complex environment (SSCE), and to explore the role of rTMS in behavioral disorders caused by SSCE and the neural mechanism. We found that rTMS effectively ameliorated the emotional and social impairments of mice in SSCE, and acute rTMS could instantaneously enhance the excitability of mPFC neurons. During depression-like and social novelty behaviors, chronic rTMS enhanced the mPFC excitatory neuronal activity that was inhibited by SSCE. Above results suggested that rTMS can completely reverse the SSCE-induced mood and social impairment by enhancing the suppressed mPFC excitatory neuronal activity. It was further found that rTMS suppressed the SSCE-induced excessive dopamine D2 receptor expression, which may be the cellular mechanism by which rTMS potentiates the SSCE-evoked hypoactive mPFC excitatory neurons. Our current results raise the possibility of rTMS being applied as a novel neuromodulation for mental health protection in spaceflight.

Surface modification of bamboo fiber with dopamine associated by laccase for poly(3-hydroxylbutyrate) biocomposites

For the purposes of obtaining poly(3-hydroxylbutyrate) (PHB) matrix composites with high performance, a novel eco-friendly surface modification pathway for bamboo fiber (BF) was demonstrated. Dopamine was first polymerized to poly(dopamine) (PDA) by laccase and then was deposited on the surface of BFs, which would improve interfacial adhesion between PHB and BFs. The replacement of chemical reagents by laccase to catalyze polymerization of dopamine could avoid the environmental damage and the degradation of natural fiber structure under alkaline conditions. The results showed that, when using laccase, the PDA layer was successfully coated on the surface of BFs in an acidic environment without destroying the structure of BFs, while self-polymerization hardly happened in the presence of dopamine alone, according to the X-ray photoelectron spectroscopy, Fourier transform infrared spectroscopy and X-ray diffraction. When the dosage of dopamine was 1.0 wt% of BFs (1-D-L), the PHB/1-D-L had a higher flexural strength 32.56 MPa and impact strength 16.46 J m−1, meanwhile, the composites had a lower crystallinity index (Xc) 17.08% when the dopamine was added 1.5 wt%. However, the mechanical properties and water resistance of PHB matrix composites could be decreased possibly due to steric hindrance when there was an excess of dopamine during surface modification.

Balancing "on" and "off" response of hydroxyl groups to a nanozyme-catalyzing system for the construction of an ultra-sensitive and selective "signal-on" detection platform for dopamine.

Targeting the functional groups present in analytes by nanozyme-catalyzed systems is a promising strategy to construct sensitive and selective platforms for the sensing of specific analytes. Herein, various groups (-COOH, -CHO, -OH, and -NH2) on benzene were introduced in an Fe-based nanozyme system with MoS2-MIL-101(Fe) as the model peroxidase nanozyme, H2O2 as the oxidizing agent, and TMB as the chromogenic substrate, and the effects of these groups at both a low concentration and high concentration were further investigated. It was found that the hydroxyl group-based substance catechol showed an "on" effect at a low concentration to increase the catalytic rate and enhance the absorbance signal, whereas an "off" effect at a high concentration with a decreased absorbance signal. Based on these results, the "on" mode and "off" mode for the biological molecule dopamine, a type of catechol derivative, were proposed. In the control system, MoS2-MIL-101(Fe) catalyzed the decomposition of H2O2 to produce ROS, which further oxidized TMB. In the "on" mode, the hydroxyl groups of dopamine could combine with the Fe(iii) site of the nanozyme to lower its oxidation state, resulting in higher catalytic activity. In the "off" mode, the excess dopamine could consume ROS, which inhibited the catalytic process. Under the optimal conditions, by balancing the "on" and "off" modes, the "on" mode for the detection of dopamine was found to have better sensitivity and selectivity. The LOD was as low as 0.5 nM. This detection platform was successfully applied for the detection of dopamine in human serum with satisfactory recovery. Our results can pave the way for the design of nanozyme sensing systems with sensitivity and selectivity.

The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.

Excess dopamine release in the dorsal striatum (DS) is linked to psychosis. Antipsychotics are thought to work by blocking striatal D2 dopamine receptors, but they lack efficacy for the negative and cognitive symptoms of schizophrenia. These observations and the fact that increasing brain-wide dopamine improves cognition have fueled the dogma that excess dopamine is not involved in negative and cognitive symptoms. However, this idea has never been explicitly tested with DS-pathway specificity. To determine if excess DS dopamine is involved in cognitive and negative symptoms, we selectively re-expressed excitatory TRPV1 receptors in DS-projecting dopamine neurons of Trpv1 knockout mice. We treated these mice with capsaicin (TRPV1 agonist) to selectively activate these neurons, validated this approach with fiber photometry, and assessed its effects on social interaction and working memory, behavioral constructs related to negative and cognitive symptoms. We combined this manipulation with antipsychotic treatment (haloperidol) and compared it to brain-wide dopamine release via amphetamine treatment. We found that selectively activating DS-projecting dopamine neurons increased DS (but not cortical) dopamine release and increased locomotor activity. Surprisingly, this manipulation also impaired social interaction and working memory. Haloperidol normalized locomotion, but only partially rescued working memory and had no effect on social interaction. By contrast, amphetamine increased locomotion but did not impair social interaction or working memory. These results suggest that excess dopamine release, when restricted to the DS, causes behavioral deficits linked to negative and cognitive symptoms. Future therapies should address this disregarded role for excess striatal dopamine in thetreatment-resistant symptoms of psychosis.

ODP041 Hearing Loss Reveals Dopamine-secreting Metastatic Paraganglioma

Abstract Background Paragangliomas are neuroendocrine tumors arising from chromaffin cells in extra-adrenal parasympathetic or sympathetic tissues. Frequently they produce catecholamines such as epinephrine and norepinephrine which cause adrenergic symptoms. Rarely, paragangliomas produce only dopamine. These tumors carry a worse prognosis than other types of paragangliomas, especially when associated with loss of SDH-B. Case A 41 year old African American female with developmental delay, allergic rhinitis, OSA, and obesity presented to a primary care clinic for evaluation of hearing loss and left ear pain. Patient was treated for acute otitis media but symptoms failed to resolve. She was referred to audiology where she was found to have a mixed conductive and sensorineural hearing loss on the left. Despite using hearing aids, a year later the patient presented to an ENT clinic with several weeks of worsening left aural fullness and decreased hearing. On otoscopy, a mass was visualized in the middle ear. CT scan identified a lytic lesion at the jugular foramen extending into the middle ear; MR of the inner auditory canal was concerning for a paraganglioma. PET CT revealed widely metastatic disease including FDG avid cervical and supraclavicular lymph nodes, pulmonary nodules, hepatic lesions, and sclerotic lesions in the vertebral column and right humerus. Biopsy of an hepatic lesion confirmed metastatic paraganglioma with loss of SDH-B. Labs were consistent with dopamine excess. A 24 hour urine dopamine was 1020 mcg/24 hour (normal 65-400) with plasma dopamine elevated at 191 pg/mL (normal <30). A 24 hour urine norepinephrine level was mildly elevated at 85 mcg/24 hours (normal 15-80) but plasma norepinephrine and epinephrine were both normal. The patient denied any history of palpitations, flushing, headaches, or chest pain. She was briefly started on doxazosin but this was later discontinued as metanephrines and normetanephrines were not significantly elevated. The tumor was not amenable for surgery. Ultimately after discussion with oncology, the patient opted to proceed with temozolomide and capecitabine chemotherapy. Discussion It is important to recognize differences in treating dopamine secreting paragangliomas compared with other catecholamine producing tumors. Preoperative alpha blockade is not routinely recommended as it may cause hypotension and postoperative cardiovascular collapse. While chemotherapy with Cyclophosphamide–dacarbazine–vincristine has historically been used for metastatic paragangliomas, temozolomide is now showing benefit in cases with SDH-B mutation. Sources cited: Foo, S. H., et al. "Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management." Singapore Med J 51.5 (2010): e89-e93. Hadoux, J., Favier, J., Scoazec, J. -Y., et al (2014),SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int. J. Cancer, 135: 2711-2720. https://doi.org/10.1002/ijc.28913. Presentation: No date and time listed

Molybdenum Oxide/Dopamine-Derived Carbon Electrodes with Enhanced Electrochemical Activity in Energy Storage Systems

Herein, a versatile sol-gel reaction produces new electrode materials consisting of tightly integrated molybdenum oxide and carbon derived from chemically incorporated dopamine molecules, and the materials show enhanced electrochemical activity in nonaqueous Li-ion and aqueous Zn-ion energy storage systems. The novel synthesis entails the oxidation of molybdenum in aqueous solutions of excess and limited dopamine (Dopa) hydrochloride via a hydrogen peroxide-initiated process.The transformation of molybdenum under the condition of Dopa excess (Mo:Dopa molar ratio of 1:1) resulted in the formation of a metastable precipitate of polydopamine (PDopa) spheres encapsulated by Dopa-preintercalated molybdenum oxide, (Dopa)xMoOy@PDopa. Hydrothermal treatment (HT) of (Dopa)xMoOy@PDopa precursor was concomitant with concurrent Dopa carbonization and molybdenum reduction processes, resulting in a formation of spherical matrices of Dopa-derived carbon decorated by MoO2 nanoplatelets (HT-MoO2/C), as determined through FTIR spectroscopy, Raman spectroscopy, and SEM imaging. Annealing (An) of HT-MoO2/C at 600°C under argon atmosphere (AnHT-MoO2/C) led not only to improvements in MoO2 crystallinity, but also to an increased oxidation state of molybdenum and a facilitated interaction between molybdenum-based and Dopa-derived components, resulting in an intimate MoO2/C heterointerface. Consequently, while both HT-MoO2/C and AnHT-MoO2/C showed reversible intercalation-type behavior when evaluated as electrodes versus Li/Li+ in nonaqueous lithium-ion cells, AnHT-MoO2/C demonstrated higher capacities, enhanced capacity retention, better rate capability, and lower charge transfer resistance. The AnHT-MoO2/C electrode showed an initial specific capacity of 260 mAh/g and 67% capacity retention after 50 cycles at 10 mA/g, compared to an initial specific capacity of 235 mAh/g and 47% capacity retention shown by HT-MoO2/C at the same current density. Furthermore, in rate capability experiments, HT-MoO2/C and AnHT-MoO2/C delivered specific capacities of 93 mAh/g and 120 mAh/g respectively at 100 mA/g.When molybdenum was transformed in the presence of Dopa deficit (Mo:Dopa molar ratio of 5:1), a (Dopa)xMoOy powder precursor was isolated, and subsequent hydrothermal treatment of this precursor produced an MoO3 material with carbonized Dopa molecules, HT-MoO3/C. Reference α-MoO3 electrodes (α-MoO3-ref) were synthesized similarly but in the absence of Dopa molecules in the initial sol-gel reaction. The appearance of characteristic D and G bands in the Raman spectra and distinct vibrational modes in the FTIR spectra of HT-MoO3/C confirmed the presence of carbon in its structure. SEM images showed a uniform nanobelt morphology with fragmentation due to interactions between interlayer Dopa and MoO3 layers under the conditions of hydrothermal treatment. HT-MoO3/C delivered a second-cycle capacitance of 141.4 F/g when cycled at 2 mV/s in a -0.25–0.70 V versus Ag/AgCl potential window in 5M ZnCl2 electrolyte, while α-MoO3-ref delivered a nearly two-fold smaller second-cycle capacitance of 76.1 F/g under the same conditions. HT-MoO3/C also showed increased capacitance compared to α-MoO3-ref when cycled at increasing sweep rates up to 20 mV/s. The superior performance of HT-MoO3/C prompted a study of the electrode in an expanded potential window, based on previous reports in which MoO3 showed electrochemical activity at negative potentials versus Ag/AgCl. The HT-MoO3/C electrode exhibited a capacitance of 347.6 F/g on the second cycle when cycled between -0.85–1.00V versus Ag/AgCl at 2 mV/s in 5M ZnCl2 electrolyte.This work demonstrates a new strategy to improve the electrochemical performance of transition metal oxide electrodes for next-generation energy storage systems. Integration of oxides with carbon through the wet chemistry synthesis approaches that involve carbonization of organic molecules can be used to control oxide crystal phase and heterointerfaces leading to improved charge transfer and energy storage properties.

Ordered PtCo Intermetallics Featuring Nitrogen‐Doped Carbon Prepared by Surface Coating Strategy for Oxygen Reduction Reaction

AbstractImproving the activity and stability of Pt‐based electrocatalysts is essential for large‐scale commercial applications of fuel cells. The ordered Pt‐based alloy nanomaterials encapsulated by coating have attracted significant attention. Here, we displayed a surface coating strategy to synthesize structurally ordered PtCo alloy catalysts featuring nitrogen‐doped carbon (NC). Experimental results reveal that the sample with appropriate dopamine feeding content shows enhanced oxygen reduction activity and stability, which exhibits a mass activity of 1.36 mA ⋅ mg−1Pt and specific activity of 1.98 mA ⋅ cm−2, superior to those of excessive or low dopamine adding content samples and commercial Pt/C catalyst. The enhanced electrocatalytic performance of this catalyst was attributed to the combined effect including the protection of suitable thickness NC shells, strong electronic interaction and high ordering degree. In this work, the surface coating strategy provides available references to further improve the oxygen reduction performance of PtM alloy catalysts.

Transformation of L-DOPA and Dopamine on the Surface of Gold Nanoparticles: An NMR and Computational Study.

Gold nanoparticles (AuNPs) have found applications in biomedicine as diagnostic tools, but extensive research efforts have been also directed toward their development as more efficient drug delivery agents. The high specific surface area of AuNPs may provide dense loading of molecules like catechols (L-DOPA and dopamine) on nanosurfaces, enabling functionalization strategies for advancing conventional therapy and diagnostic approaches of neurodegenerative diseases. Despite numerous well-described procedures in the literature for preparation of different AuNPs, possible transformation and structural changes of surface functionalization agents have not been considered thoroughly. As a case in point, the catechols L-DOPA and dopamine were selected because of their susceptibility to oxidation, cyclization, and polymerization. To assess the fate of coating and functionalization agents during the preparation of AuNPs or interaction at the nano-bio interface, a combination of spectroscopy, light scattering, and microscopy techniques was used while structural information and reaction mechanism were obtained by NMR in combination with computational tools. The results revealed that the final form of catechol on the AuNP nanosurface depends on the molar ratio of Au used for AuNP preparation. A large molar excess of L-DOPA or dopamine is needed to prepare AuNPs funtionalized with fully reduced catechols. In the case of molar excess of Au, the oxidation of catechols to dopamine quinone and dopaquinone was promoted, and dopaquinone underwent intramolecular cyclization in which additional oxidation products, leukodopachrome, dopachrome, or its tautomer, were formed because of the larger intrinsic acidity of the more nucleophilic amino group in dopaquinone. MD simulations showed that, of the oxidation products, dopachrome had the highest affinity for binding to the AuNPs surface. The results highlight how a more versatile methodological approach, combining experimental and in silico techniques, allows more reliable characterization of binding events at the surface of AuNPs for possible applications in biomedicine.

Cariprazine

Cariprazine is a partial agonist of dopamine and serotonin with high affinity for D3 receptor. There is excess endogenous dopamine both in schizophrenia and bipolar disorder. Cariprazine binds to D3/D2 receptor as antagonist and agonist in schizophrenia and bipolar depression, respectively. Thus, the dopamine pathway inhibited and stimulated in the respective cases. The United States Food and Drug Administration (USFDA) approval now covers the full-spectrum Bipolar I disorder, yet to hit the Indian market.

Video Game Addictive Symptom Level, Use Intensity, and Hedonic Experience: Cross-sectional Questionnaire Study.

BackgroundThe effects of behavioral addiction to video games has received increasing attention in the literature, given increased use intensity among subgroups of video game players.ObjectiveThis study seeks to empirically determine the relationship between intensity of video gaming and hedonic experience of the player.MethodsWe conducted a survey of 835 individuals who regularly play video games to determine the relationship between intensity of use and hedonic experience. We divided the sample into quartiles by self-reported video game addictive symptom level (from the Internet Gaming Disorder Scale) and conducted polynomial regressions separately for each quartile.ResultsWe found that the higher video game addictive symptom level groups experienced a U-shaped (curvilinear) relationship between hedonic experience and intensity of play, whereas groups with lower video game addictive symptom levels exhibited no such relationship. The coefficients for the highest addictive symptom level group (quartile 4) for marginal effects for hours played per week and hours played per week squared were significantly negative (P=.005) and significantly positive (P=.004), respectively.ConclusionsOur results are consistent with sensitization and tolerance theories, which suggest that high-symptom groups experience frustration and disappointment until they achieve excessive dopamine release, at which point their hedonic experience is expected to improve with additional play. Conversely, low-symptom groups experience no such fall-and-rise pattern. This result is consistent with the outcome that members of the latter group play the game for the direct experience, such that their hedonic experience is more directly related to events occurring in the game than to the increasingly elusive pursuit of excessive dopamine release. We also find that high-symptom groups spend substantially more time and money to support video game use and are much more likely to engage in video game use at the expense of other important activities, such as working, sleeping, and eating.

P537. Metabolomic Measures of Oxidative Stress in the Dorsal and Ventral Striatum and Dorsolateral Prefrontal Cortex in Schizophrenia

Oxidative stress is proposed to contribute to schizophrenia (SZ) pathophysiology. Some oxidant sources, such as mitochondria, are ubiquitous in the brain, but others, such as dopamine degradation, are brain region-dependent. SZ is associated with excess striatal dopamine that is most pronounced in dorsal striatum (DS) relative to ventral striatum (VS) and is not present in dorsolateral prefrontal cortex (DLPFC). We investigated the possibility that markers of oxidative stress and damage are most pronounced in DS relative to VS and DLPFC in SZ subjects.

Cocaine: An Updated Overview on Chemistry, Detection, Biokinetics, and Pharmacotoxicological Aspects including Abuse Pattern.

Cocaine is one of the most consumed stimulants throughout the world, as official sources report. It is a naturally occurring sympathomimetic tropane alkaloid derived from the leaves of Erythroxylon coca, which has been used by South American locals for millennia. Cocaine can usually be found in two forms, cocaine hydrochloride, a white powder, or ‘crack’ cocaine, the free base. While the first is commonly administered by insufflation (‘snorting’) or intravenously, the second is adapted for inhalation (smoking). Cocaine can exert local anaesthetic action by inhibiting voltage-gated sodium channels, thus halting electrical impulse propagation; cocaine also impacts neurotransmission by hindering monoamine reuptake, particularly dopamine, from the synaptic cleft. The excess of available dopamine for postsynaptic activation mediates the pleasurable effects reported by users and contributes to the addictive potential and toxic effects of the drug. Cocaine is metabolised (mostly hepatically) into two main metabolites, ecgonine methyl ester and benzoylecgonine. Other metabolites include, for example, norcocaine and cocaethylene, both displaying pharmacological action, and the last one constituting a biomarker for co-consumption of cocaine with alcohol. This review provides a brief overview of cocaine’s prevalence and patterns of use, its physical-chemical properties and methods for analysis, pharmacokinetics, pharmacodynamics, and multi-level toxicity.

Management of Medication-Induced Psychiatric Disorders.

Management of Medication-Induced Psychiatric Disorders.

Emerging Treatments in Schizophrenia.

Although antipsychotics have been available for almost 70 years and greatly improved outcomes for individuals with schizophrenia, all currently available options derive their efficacy from blockade of dopaminergic receptors. However, this mechanism of action leaves many symptoms unresolved and is associated with a significant side effect burden. The mechanisms underlying schizophrenia, which were initially thought to be related to excessive presynaptic dopamine in specific areas of the brain, are now understood to be much more complex and involve structural and molecular changes throughout brain circuits. Consequently, drug discovery efforts have sought new targets in the search for safer and more effective medications that can improve symptoms of schizophrenia and psychosis, including trace amine-associated receptors (TAARs), muscarinic receptors, and serotonergic receptors. Positive phase 2 trial results indicating efficacy and safety of the TAAR1 agonist ulotaront (SEP-363856) and of the muscarinic M1/M4 agonist KarXT (xanomeline plus trospium) for total, positive, and negative symptoms in patients with acute exacerbation of schizophrenia, and of the serotonin 5-HT2A agonist/antagonist pimavanserin in patients with schizophrenia and predominant negative symptoms for negative symptom control are encouraging. Taken together, these data indicate in the context of ongoing phase 3 trial programs that patients with schizophrenia may soon have access to the first non-D2 blocking medication, which could drastically change the treatment landscape and improve outcomes for many of the individuals with schizophrenia who do not fully respond to or cannot tolerate currently available antipsychotic agents that currently all act via postsynaptic dopamine D2 receptor blockade.

Emerging Treatments in Schizophrenia.

Although antipsychotics have been available for almost 70 years and greatly improved outcomes for individuals with schizophrenia, all currently available options derive their efficacy from blockade of dopaminergic receptors. However, this mechanism of action leaves many symptoms unresolved and is associated with a significant side effect burden. The mechanisms underlying schizophrenia, which were initially thought to be related to excessive presynaptic dopamine in specific areas of the brain, are now understood to be much more complex and involve structural and molecular changes throughout brain circuits. Consequently, drug discovery efforts have sought new targets in the search for safer and more effective medications that can improve symptoms of schizophrenia and psychosis, including trace amine-associated receptors (TAARs), muscarinic receptors, and serotonergic receptors. Positive phase 2 trial results indicating efficacy and safety of the TAAR1 agonist ulotaront (SEP-363856) and of the muscarinic M1/M4 agonist KarXT (xanomeline plus trospium) for total, positive, and negative symptoms in patients with acute exacerbation of schizophrenia, and of the serotonin 5-HT2A agonist/antagonist pimavanserin in patients with schizophrenia and predominant negative symptoms for negative symptom control are encouraging. Taken together, these data indicate in the context of ongoing phase 3 trial programs that patients with schizophrenia may soon have access to the first non-D2 blocking medication, which could drastically change the treatment landscape and improve outcomes for many of the individuals with schizophrenia who do not fully respond to or cannot tolerate currently available antipsychotic agents that currently all act via postsynaptic dopamine D2 receptor blockade.

Tics and Emotions.

Tics can be associated with neurological disorders and are thought to be the result of dysfunctional basal ganglia pathways. In Tourette Syndrome (TS), excess dopamine in the striatum is thought to excite the thalamo-cortical circuits, producing tics. When external stressors activate the hypothalamic-pituitary-adrenal (HPA) axis, more dopamine is produced, furthering the excitation of tic-producing pathways. Emotional processing structures in the limbic are also activated during tics, providing further evidence of a possible emotional component in motor ticking behaviors. The purpose of this review is to better understand the relationship between emotional states and ticking behavior. We found support for the notion that premonitory sensory phenomena (PSP), sensory stimulation, and other environmental stressors that impact the HPA axis can influence tics through dopaminergic neurotransmission. Dopamine plays a vital role in cognition and motor control and is an important neurotransmitter in the pathophysiology of other disorders such as obsessive–compulsive disorder (OCD) and attention deficit hyperactivity disorder (ADHD), which tend to be comorbid with ticking disorders and are thought to use similar pathways. It is concluded that there is an emotional component to ticking behaviors. Emotions primarily involving anxiety, tension, stress, and frustration have been associated with exacerbated tics, with PSP contributing to these feelings.

The dual role of dopamine in the modulation of information processing in the prefrontal cortex underlying social behavior.

Dopamine in the prefrontal cortex is essential for the regulation of social behavior. However, stress-causing social withdrawal also promotes dopamine release in the prefrontal cortex. Thus, this evidence suggests opposite functions of dopamine in the prefrontal cortex. However, the influence of dopamine on prefrontal functions is yet to be fully understood. Here, we show that dopamine differentially modulated the neuronal activity triggered by social stimuli in the prefrontal cortex, depending on the duration of the dopamine activation (transient or sustained activation). Using chemogenetic techniques, we have found that social behavior was negatively regulated by a sustained increase in dopamine neuronal activity in the ventral tegmental area, while it was positively regulated by an acute increase. The duration of social interactions was positively correlated with the transient dopamine release triggered by social stimuli in the prefrontal cortex and negatively correlated with the sustained increase in prefrontal dopamine levels. Furthermore, the elevation of neural calcium signal, triggered by social stimuli, in the prefrontal cortex was attenuated by the persistent elevation of prefrontal dopamine levels, whereas an acute increase in dopamine levels enhanced it. Additionally, the chronic excess of dopamine suppressed c-Fos induction triggered by social stimuli in prefrontal neurons expressing dopamine D1 receptors, but not D2 receptors. These results suggest that sustained activation of prefrontal dopamine, at the opposite of its transient activation, can reduce prefrontal activity associated with social behavior, even for identical dopamine concentrations. Thus, dopamine plays opposite roles in modulating prefrontal activity depending on the duration of its action.

Protective effects of antioxidants on striatal dopamine release induced by organophosphorus pesticides

Although the toxic effects of organophosphorus (OP) pesticides have been classically attributed to inhibition of the acetylcholinesterase, other neurotoxic mechanisms, as oxidative stress can also occur. Here we evaluated if antioxidants prevent the excessive dopamine release induced by OP pesticides in conscious and freely moving rats, using cerebral microdialysis technique. Intrastriatal infusion of paraoxon (5 mM), glufosinate (10 mM) or glyphosate (5 mM) significantly increased the dopamine release (1006 ± 106%, 991 ± 142%, and 1164 ± 128%, relative to baseline, respectively). To evaluate if these increased dopamine release could be related to oxidative stress, we pretreated animals with antioxidants glutathione (GSH, 400 or 800 μM), dithiothreitol (DTT, 5 or 10 μM), trolox (1 or 3 mM), and α-lipoic acid (ALA, 400 or 800 μM) before administration of OP pesticides. Intrastriatal administration of the antioxidants GSH, DTT, trolox, and ALA was highly effective in preventing the glyphosate and glufosinate-induced dopamine overflow. However, only GSH (800 μM) significantly decreased the effect of paraoxon on dopamine levels. The high toxicity of this pesticide and the low concentrations used could explain this lack of effect in our experimental conditions. The fact that ROS scavengers prevent the excessive dopamine release induced by OP pesticides, further supports the view that dopamine overflow can cause neuronal damage mediated, at least in part, by oxidative stress.

Primary and Secondary Negative Symptoms in Schizophrenia.

The negative symptoms of schizophrenia include volitional (motivational) impairment manifesting as avolition, anhedonia, social withdrawal, and emotional disorders such as alogia and affective flattening. Negative symptoms worsen patients' quality of life and functioning. From the diagnostic point of view, it is important to differentiate between primary negative symptoms, which are regarded as an integral dimension of schizophrenia, and secondary negative symptoms occurring as a result of positive symptoms, comorbid depression, side effects of antipsychotics, substance abuse, or social isolation. If secondary negative symptoms overlap with primary negative symptoms, it can create a false clinical impression of worsening deficit symptoms and disease progression, which leads to the choice of incorrect therapeutic strategy with excessive dopamine blocker loading. Different longitudinal trajectories of primary and secondary negative symptoms in different schizophrenia stages are proposed as an important additional discriminating factor. This review and position paper focuses primarily on clinical aspects of negative symptoms in schizophrenia, their definition, phenomenology, factor structure, and classification. It covers the historical and modern concepts of the paradigm of positive and negative symptoms in schizophrenia, as well as a detailed comparison of the assessment tools and psychometric tests used for the evaluation of negative symptoms.